1. What Is the Gallbladder Cancer Market?
The Gallbladder Cancer Market covers oncology therapeutics, diagnostics, and surgical interventions for gallbladder carcinoma, the most common biliary tract cancer with poor prognosis due to late-stage presentation. Gallbladder cancer encompasses chemotherapy, targeted therapy for FGFR2 and IDH1 mutations, immunotherapy, and surgical resection for early-stage disease. Market dynamics reflect late-stage diagnosis at advanced disease reducing surgical eligibility, FGFR inhibitor pemigatinib and IDH1 inhibitor ivosidenib FDA approval expanding targeted therapy options, and liquid biopsy enabling earlier diagnosis.
2. Gallbladder Cancer Market Size & Forecast
3. Emerging Technologies
- FGFR2 inhibitor next-generation compounds overcoming acquired resistance to first-generation pemigatinib are advancing as resistance management tools. Growing clinical development is driven by inevitable FGFR inhibitor resistance development requirements.
- Antibody-drug conjugate development targeting HER2 and other biliary cancer antigens are advancing as novel biliary cancer therapy modalities. Growing investment is driven by chemotherapy efficacy ceiling limitations in advanced gallbladder cancer.
- Intraoperative fluorescence-guided surgery enabling surgeons to visualise biliary tumour margins during resection are advancing as surgical precision tools. Growing adoption at biliary cancer surgery centres is driven by R0 resection margin clearance improvement requirements.
- Liquid biopsy ctDNA panels enabling gallbladder cancer recurrence monitoring after resection are advancing as surveillance tools. Growing adoption at gallbladder cancer follow-up is driven by early recurrence detection requirements.
Such innovations are driving change across adjacent industries too. Discover more in our Companion Diagnostic Market.
4. Key Market Opportunity
Revenue is concentrated in the Gallbladder Cancer Market at the FGFR and IDH1 targeted therapy sub-market, where biomarker-defined patient populations create defined commercial revenue for pemigatinib and ivosidenib despite small indication size. Immunotherapy first-line combination creates a large-volume commercial opportunity as gemcitabine-cisplatin-durvalumab becomes the standard-of-care for all advanced biliary cancer. Novel ADC and targeted therapy development creates pipeline investment opportunity as the biliary cancer targeted therapy landscape expands. Asia Pacific gallbladder cancer creates geographic concentration as India, Japan, Korea, and Chile have the highest global incidence rates.
5. Top Companies in the Gallbladder Cancer Market
The following organisations hold leading positions in the Gallbladder Cancer Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Incyte (Pemigatinib)
- Servier (Ivosidenib)
- AstraZeneca (Durvalumab)
- Regeneron (Cemiplimab)
- Eli Lilly (LY3023414)
- QED Therapeutics
- Relay Therapeutics
- Turning Point Therapeutics
- Blueprint Medicines
- Genentech (Herceptin)
6. Market Segmentation
The Gallbladder Cancer Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Treatment | ChemotherapyFGFR InhibitorIDH1 InhibitorImmunotherapySurgery |
| By Stage | ResectableLocally AdvancedMetastatic |
| By Diagnosis | Imaging CT MRIEndoscopyLiquid Biopsy |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Gallbladder Cancer Market trajectory over the forecast period:
Incyte Pemigatinib Achieves FDA Accelerated Approval for FGFR2 Cholangiocarcinoma Including Gallbladder.Incyte pemigatinib FDA accelerated approval for FGFR2 fusion-positive biliary tract cancer in 2020 and maintenance through 2024 demonstrates first targeted therapy for FGFR-altered biliary malignancy including gallbladder cancer. FGFR2 alteration prevalence in 15 percent of biliary tract cancers creates a biomarker-defined patient subset for targeted therapy.
Servier Ivosidenib Achieves FDA Approval for IDH1-Mutant Cholangiocarcinoma Expanding Biliary Targeted Therapy.Servier ivosidenib FDA approval for IDH1-mutant cholangiocarcinoma in 2021 maintained through 2024 demonstrates IDH1 inhibitor expanding biliary targeted therapy beyond FGFR. IDH1 mutation prevalence in 20 percent of intrahepatic cholangiocarcinoma and gallbladder cancer creates second biomarker-defined targeted therapy patient subset.
Gemcitabine-Cisplatin-Durvalumab Combination Becomes Standard-of-Care for Advanced Biliary Tract Cancer.AstraZeneca durvalumab plus gemcitabine-cisplatin achieving FDA approval for biliary tract cancer in 2023 and maintaining standard-of-care status in 2024 demonstrates immunotherapy improving first-line biliary cancer therapy. The TOPAZ-1 trial demonstrating 7.2 percent absolute improvement in 24-month overall survival establishes immunotherapy benefit in gallbladder and cholangiocarcinoma combination regimens.
For related market intelligence, see the Pancreatic Neuroendocrine Tumor Market.
8. Segmental Analysis
By treatment, the Chemotherapy and Immunotherapy Combination segment dominated the Gallbladder Cancer Market in 2025. Representing the largest revenue category as gemcitabine-cisplatin-durvalumab standard-of-care achieves broad adoption. The FGFR Inhibitor Targeted Therapy segment is the fastest-growing category, advancing as pemigatinib and advanced FGFR inhibitors expand FGFR-altered patient biomarker selection.
By stage, the Metastatic segment dominated in 2025 due to late-stage presentation predominance.
By diagnosis method, the Imaging CT/MRI segment dominated the Gallbladder Cancer Market in 2025, as cross-sectional imaging represents the primary modality for gallbladder cancer staging, resectability assessment, and treatment response evaluation. Liquid Biopsy is the fastest-growing diagnosis category, driven by research investment in circulating tumour DNA and cell-free DNA detection enabling earlier gallbladder cancer identification.
9. Regional Analysis
Regional demand patterns across the Gallbladder Cancer Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Gallbladder Cancer Market in 2025, holding 40.5% of the global market. Oncology centres, hepatobiliary surgery programmes, and pharmaceutical companies are pursuing gallbladder cancer treatment innovation, clinical research, and drug development across the region's large oncology research infrastructure. FDA oncology drug approval pathways, growing NIH investment in rare and difficult-to-treat cancers, and strong pharmaceutical industry commitment to gallbladder cancer research are encouraging therapeutic development. High oncology research investment, established clinical trial infrastructure, and growing precision oncology capabilities are generating regional gallbladder cancer treatment development activity.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 9.92% during the forecast period. The high incidence of gallbladder cancer across India, Japan, South Korea, and Chile is creating significant unmet clinical need and institutional demand for improved diagnostic and therapeutic approaches. Growing pharmaceutical investment in oncology drug development and increasing clinical research collaboration between regional and global pharmaceutical companies are encouraging gallbladder cancer therapeutic innovation. Rising oncology treatment infrastructure investment and expanding precision medicine adoption across the region are generating demand for improved gallbladder cancer diagnostics and treatments.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Gallbladder Cancer Market was valued at USD 2.20 Bn in 2025 and is projected to reach USD 4.37 Bn by 2034, growing at a CAGR of 7.9% over the 2026–2034 forecast period.
The Gallbladder Cancer Market is projected to grow at a CAGR of 7.9% from 2026 to 2034.
North America accounted for the largest share of the Gallbladder Cancer Market in 2025, holding 40.5% of the global market.
The leading companies in the Gallbladder Cancer Market include Incyte (Pemigatinib), Servier (Ivosidenib), AstraZeneca (Durvalumab), Regeneron (Cemiplimab), Eli Lilly (LY3023414), QED Therapeutics, Relay Therapeutics, Turning Point Therapeutics, Blueprint Medicines, Genentech (Herceptin).
Incyte pemigatinib achieves fda accelerated approval for fgfr2 cholangiocarcinoma including gallbladder.
By treatment, the Chemotherapy and Immunotherapy Combination segment dominated the Gallbladder Cancer Market in 2025.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.